Published in Hepatology on February 15, 2012
Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe (2016) 2.17
Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol (2012) 1.98
Interactions between the intestinal microbiome and liver diseases. Gastroenterology (2014) 1.92
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol (2013) 1.68
Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol (2013) 1.66
Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med (2013) 1.17
Bacterial infections in end-stage liver disease: current challenges and future directions. Gut (2012) 1.00
Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol (2014) 0.97
Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol (2014) 0.95
The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol (2015) 0.93
Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol (2013) 0.90
Beyond a broken heart: circulatory dysfunction in the failing Fontan. Pediatr Cardiol (2014) 0.86
The role of microbiota in hepatic encephalopathy. Gut Microbes (2014) 0.85
The microbiome and critical illness. Lancet Respir Med (2015) 0.85
Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity. World J Gastroenterol (2016) 0.84
Gut microbiota: its role in hepatic encephalopathy. J Clin Exp Hepatol (2014) 0.83
Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol (2016) 0.83
Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications. World J Hepatol (2015) 0.82
TREM-1 promotes survival during Klebsiella pneumoniae liver abscess in mice. Infect Immun (2014) 0.82
Effect of artesunate supplementation on bacterial translocation and dysbiosis of gut microbiota in rats with liver cirrhosis. World J Gastroenterol (2016) 0.80
Pathogen profile and drug resistance analysis of spontaneous peritonitis in cirrhotic patients. World J Gastroenterol (2015) 0.80
Alteration of the serum microbiome composition in cirrhotic patients with ascites. Sci Rep (2016) 0.79
Effect of gastric acid suppressants and prokinetics on peritoneal dialysis-related peritonitis. World J Gastroenterol (2014) 0.78
Bloodstream infections in internal medicine. Virulence (2016) 0.78
Gastrointestinal dysfunction in liver cirrhosis. World J Gastroenterol (2014) 0.78
Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study. World J Gastroenterol (2016) 0.77
Systemic levels of human β-defensin 1 are elevated in patients with cirrhosis. Ann Gastroenterol (2016) 0.76
Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. Saudi J Gastroenterol (2014) 0.76
Implication of the intestinal microbiome in complications of cirrhosis. World J Hepatol (2016) 0.75
Bacterial translocation aggravates CCl4-induced liver cirrhosis by regulating CD4(+) T cells in rats. Sci Rep (2017) 0.75
Immune Dysfunction in Cirrhosis. J Clin Transl Hepatol (2017) 0.75
Chronic Heavy Alcohol Use is Associated with Upregulated Paneth Cell Antimicrobials in Gastric Mucosa. Clin Transl Gastroenterol (2015) 0.75
Fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride. Sci Rep (2017) 0.75
Dysbiosis of Intestinal Microbiota and Decreased Antimicrobial Peptide Level in Paneth Cells during Hypertriglyceridemia-Related Acute Necrotizing Pancreatitis in Rats. Front Microbiol (2017) 0.75
Novel prevention strategies for bacterial infections in cirrhosis. Expert Opin Pharmacother (2016) 0.75
Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature (2010) 6.25
Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol (2009) 6.10
Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature (2003) 5.14
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host Microbe (2009) 4.20
A common mutation in the defensin DEFB126 causes impaired sperm function and subfertility. Sci Transl Med (2011) 3.13
Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol (2002) 3.13
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology (2003) 2.97
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun (2004) 2.47
Human α-defensin 6 promotes mucosal innate immunity through self-assembled peptide nanonets. Science (2012) 2.44
Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature (2011) 2.31
Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol (2007) 2.28
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology (2002) 2.15
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2003) 2.06
NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem (2005) 2.06
Life in the inflamed intestine, Salmonella style. Trends Microbiol (2009) 1.97
Paneth cells: maestros of the small intestinal crypts. Annu Rev Physiol (2013) 1.93
Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kappaB pathway in adipocytes links nutritional signalling with innate immunity. Immunology (2008) 1.91
Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol (2009) 1.88
DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol (2011) 1.85
Cell-cell contacts prevent anoikis in primary human colonic epithelial cells. Gastroenterology (2006) 1.84
Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis (2002) 1.80
Contribution of flagellin pattern recognition to intestinal inflammation during Salmonella enterica serotype typhimurium infection. Infect Immun (2009) 1.79
Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol (2006) 1.78
Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum (2003) 1.75
The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol (2007) 1.73
Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol (2006) 1.73
Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol (2003) 1.72
The capsule encoding the viaB locus reduces interleukin-17 expression and mucosal innate responses in the bovine intestinal mucosa during infection with Salmonella enterica serotype Typhi. Infect Immun (2007) 1.69
Interleukin-23 orchestrates mucosal responses to Salmonella enterica serotype Typhimurium in the intestine. Infect Immun (2008) 1.67
NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int (2011) 1.63
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 1.59
Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol (2013) 1.57
Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) (2009) 1.57
Inflammatory Bowel Disease. Dtsch Arztebl Int (2016) 1.56
Strong predictors for alcohol recidivism after liver transplantation: non-acceptance of the alcohol problem and abstinence of <3 months. Scand J Gastroenterol (2011) 1.55
Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum. Proc Natl Acad Sci U S A (2010) 1.50
Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun (2007) 1.48
Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues. FEBS Lett (2006) 1.44
The expression patterns of peritoneal defensins. Perit Dial Int (2007) 1.39
[Suspected cases of severe side effects after infliximab (Remicade) in Germany]. Med Klin (Munich) (2003) 1.38
Regulation of C-type lectin antimicrobial activity by a flexible N-terminal prosegment. J Biol Chem (2008) 1.35
Salmonella uses energy taxis to benefit from intestinal inflammation. PLoS Pathog (2013) 1.31
Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation (2008) 1.30
Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci U S A (2010) 1.29
Paneth's disease. J Crohns Colitis (2010) 1.29
Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol (2005) 1.27
Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol (2004) 1.26
CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology (2005) 1.25
Extensive in vivo human milk peptidomics reveals specific proteolysis yielding protective antimicrobial peptides. J Proteome Res (2013) 1.25
Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr Opin Gastroenterol (2007) 1.25
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Role of TLR9 in hepatic stellate cells and experimental liver fibrosis. Biochem Biophys Res Commun (2008) 1.23
Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol (2004) 1.23
Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur J Gastroenterol Hepatol (2006) 1.21
Helicobacter pylori induces an antimicrobial response in rhesus macaques in a cag pathogenicity island-dependent manner. Gastroenterology (2008) 1.21
A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids. J Pediatr Gastroenterol Nutr (2009) 1.20
IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis (2012) 1.19
Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med (2013) 1.17
Defensins and cathelicidins in gastrointestinal infections. Curr Opin Gastroenterol (2007) 1.16
Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J Leukoc Biol (2007) 1.14
Bacteria regulate intestinal epithelial cell differentiation factors both in vitro and in vivo. PLoS One (2013) 1.13
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer (2013) 1.12
In vivo colonoscopic optical coherence tomography for transmural inflammation in inflammatory bowel disease. Clin Gastroenterol Hepatol (2004) 1.12
Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut (2007) 1.11
Localization of the lipopolysaccharide recognition complex in the human healthy and inflamed premature and adult gut. Inflamm Bowel Dis (2010) 1.11
Human alpha defensin 5 expression in the human kidney and urinary tract. PLoS One (2012) 1.08
Transforming growth factor-beta 1 induces intestinal myofibroblast differentiation and modulates their migration. World J Gastroenterol (2009) 1.07
The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica (2012) 1.07